查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095733

肺癌免疫查核點抑制劑市場－2026-2032年全球市場預測

Immune Checkpoint Inhibitors for Lung Cancer Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺癌免疫查核點抑制劑市場規模將成長至 35.5 億美元，複合年成長率為 15.08%。

主要市場統計數據
基準年 2025 13.2億美元
預計年份：2026年 15.2億美元
預測年份 2032 35.5億美元
複合年成長率 (%) 15.08%

免疫療法中的查核點抑制劑已成為現代腫瘤治療的核心支柱，尤其是在非小細胞肺癌和某些小細胞肺癌的治療中。這些免疫療法針對PD-1、PD-L1和CTLA-4等抑制性通路，有助於恢復抗腫瘤T細胞的活性，從而徹底改變了一線治療、維持治療、強化治療、手術全期以及復發性疾病的治療策略。臨床應用與生物標記檢測密切相關，包括PD-L1表達、特定情況下的腫瘤突變負荷、微衛星不穩定性狀態以及廣泛的分子譜分析，以區分哪些患者適合接受單藥免疫治療、化療聯合免疫治療、雙重免疫治療或序貫標標靶治療治療。

目前肺癌免疫治療的發展趨勢日益趨向於實證個別化治療。監管機構的批准和臨床指南的更新正在拓展查核點抑制劑在轉移性疾病、放射線治療後無法切除的III期肺癌以及術前術後可切除腫瘤中的應用。同時，臨床醫生和醫療系統也在努力平衡持續療效與免疫相關不利事件的管理、盡可能減少類固醇使用的毒性管理方案、臨床實踐中患者的合格以及診斷資源的公平獲取。隨著延長存活期越來越依賴精準的患者選擇和多學科診療，免疫查核點抑制劑仍然是臨床研發、保險公司評估以及腫瘤科服務重組的重中之重。

肺癌免疫療法的變革性變化

由於早期應用、聯合治療以及生物標記的更深入整合，肺癌免疫查核點抑制劑的治療模式正在發生變革性轉變。免疫療法不再局限於進行性病例。經過同儕審查的臨床證據支持其擴展至輔助性治療、輔助性治療和強化治療，這為胸腔外科醫生、腫瘤內科醫生、放射腫瘤科醫生、病理學家和保險公司帶來了新的決策考慮。這項轉變凸顯了協調一致的診斷流程的重要性，該流程應確保在治療開始前及時進行PD-L1檢測、次世代定序和病理檢查。

人工智慧對查核點抑制劑療法的累積影響

人工智慧正在對肺癌免疫查核點抑制劑治療的整個過程產生累積影響，從早期診斷和治療選擇到毒性監測和真實世界數據（REW）的生成。在診斷影像領域，人工智慧驅動的放射組學正在研究中，旨在從CT、PET和MRI掃描中提取可能與腫瘤生物學特徵、反應模式、偽序列、過序列和疾病進展相關的定量特徵。在病理學領域，人工智慧驅動的影像分析可以支援可重複的PD-L1評分工作流程、腫瘤浸潤淋巴細胞的評估以及用於分子檢測的組織樣本的優先排序，但仍需要專家進行臨床檢驗和品管，以符合監管標準。

全球肺癌免疫療法的關鍵區域見解

在亞太地區，由於肺癌高發生、癌症診療基礎設施的不斷完善以及生物標記檢測在主要醫療體系中的日益普及，肺癌免疫查核點抑制劑領域正取得快速進展。在中國、日本、韓國、印度和澳大利亞，透過監管部門的批准、國內臨床研究以及醫院分子診斷的推廣，免疫檢查點抑制劑的臨床應用正在穩步推進。然而，不同地區的醫療資源取得仍然不均衡，都市區癌症中心通常比農村或資源匱乏地區提供更全面的免疫治療服務，因此，擴大診斷範圍和明確醫保報銷機制將是該地區取得進展的關鍵。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東南亞國協，肺癌免疫查核點抑制劑正日益被納入三級癌症治療體系，但資源豐富的都市區醫療中心與資源匱乏的農村醫療系統在治療可及性方面存在顯著差異。新加坡、泰國、馬來西亞、印尼、越南和菲律賓在診斷系統發展、健保報銷體系成熟度以及臨床試驗參與度方面均存在差距。該地區的關鍵機會在於推動PD-L1檢測的標準化、提升病理檢測能力以及建立進行性肺癌診療的轉診機制。

主要國家查核點抑制劑的發展趨勢

在美國，免疫查核點抑制劑已透過指引指導、全面的生物標記檢測、廣泛的臨床試驗以及完善的免疫相關毒性管理，深度融入肺癌治療系統。加拿大採用公共資助的癌症治療模式，省級醫保報銷決策、集中化的癌症機構以及生物標記的獲取途徑都會影響治療方案的一致性。在墨西哥，儘管免疫療法在私立和部分公立醫療機構中的應用日益普及，但診斷的可及性和成本效益仍然是重要的障礙。

為行業領導者提供的實用建議

產業領導者應優先考慮基於實證醫學的差異化，圍繞生物標記定義的肺癌患者群體，協調臨床開發、診斷夥伴關係和患者准入策略。投資於高品質的PD-L1檢測、次世代定序流程、液態生物檢體檢驗和標準化病理報告，可以減少治療延誤並提高治療準確性。臨床計畫應繼續關注早期肺癌、查核點抑制劑抗藥性、致癌基因驅動的腫瘤、老年患者、合併自體免疫疾病的患者以及臨床試驗中代表性不足的患者群體，以滿足這些群體未被滿足的需求。

調查方法

本執行摘要採用系統性的二手調查方法撰寫，重點在於與肺癌免疫查核點抑制劑相關的檢驗且有數據支持的資訊來源。研究途徑包括對同行評審的腫瘤學文獻、監管文件、臨床實踐指南、衛生技術評估、公共衛生出版物、臨床試驗註冊庫、癌症機構資源和藥物警戒參考資料的審查。證據優先來自權威資訊來源，例如國家和國際腫瘤學指南、監管附加檔、頂尖醫學期刊、癌症註冊庫和公共衛生機構。

結論

免疫查核點抑制劑從根本上改變了肺癌的治療，它不僅能為部分患者帶來持續療效，還能拓展不同疾病階段的治療選擇。其持續有效性取決於精準的患者篩選、及時的生物標記檢測、有效管理免疫相關不利事件，以及公平地獲得先進的診斷技術和腫瘤學專業知識。該領域正朝著早期療育、合理聯合治療、改進抗藥性管理以及更廣泛地利用真實世界數據（REW）來最佳化臨床實踐的方向發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 研究的先決條件
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：肺癌免疫療法查核點抑制劑市場：按類型分類

  • PD-1抑制劑
  • PD-L1抑制劑
  • CTLA-4抑制劑

第8章：肺癌免疫查核點抑制劑市場：依治療方案分類

  • 聯合治療
    • 合併化療
    • 聯合標靶治療治療
  • 單藥治療

第9章：肺癌免疫查核點抑制劑市場：依治療線分類

  • 第一行
  • 第二行
  • 第三線及以後

第10章：肺癌免疫療法查核點抑制劑市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第11章 肺癌免疫療法查核點抑制劑市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 腫瘤診所

第12章 肺癌免疫療法查核點抑制劑市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 肺癌免疫療法查核點抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肺癌免疫療法查核點抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Innovent Biologics, Inc.
  • Lepu Biopharma Co., Ltd.
  • Merck & Co.
  • Ono Pharmaceutical Co. Ltd
  • Regeneron Pharmaceuticals
  • Shanghai Junshi Biosciences Co. Ltd.
Product Code: MRR-E40E525C3802

The Immune Checkpoint Inhibitors for Lung Cancer Market is projected to grow by USD 3.55 billion at a CAGR of 15.08% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.52 billion
Forecast Year [2032] USD 3.55 billion
CAGR (%) 15.08%

Immune checkpoint inhibitors for lung cancer have become a central pillar of modern oncology, particularly for non-small cell lung cancer and selected small cell lung cancer settings. By targeting inhibitory pathways such as PD-1, PD-L1, and CTLA-4, these immunotherapies help restore anti-tumor T-cell activity and have reshaped treatment strategies across first-line, maintenance, consolidation, perioperative, and recurrent disease pathways. Clinical adoption is closely linked to biomarker testing, including PD-L1 expression, tumor mutational burden in selected contexts, microsatellite instability status, and broader molecular profiling to distinguish patients who may benefit from immunotherapy alone, chemo-immunotherapy, dual immunotherapy, or targeted therapy sequencing.

The lung cancer immunotherapy landscape is increasingly defined by evidence-based personalization. Regulatory approvals and clinical guidelines have expanded the role of checkpoint blockade across metastatic disease, unresectable stage III disease following chemoradiation, and resectable tumors before or after surgery. At the same time, clinicians and health systems are balancing durable response potential with immune-related adverse event management, steroid-sparing toxicity protocols, real-world patient eligibility, and equitable access to diagnostic infrastructure. As survival gains become more dependent on precision selection and multidisciplinary care, immune checkpoint inhibitors remain a high-priority area for clinical development, payer evaluation, and oncology service redesign.

Transformative Shifts in Lung Cancer Immunotherapy

The landscape for immune checkpoint inhibitors in lung cancer is undergoing transformative shifts driven by earlier-stage use, combination regimens, and deeper biomarker integration. Immunotherapy is no longer confined to advanced metastatic settings; peer-reviewed clinical evidence has supported its movement into neoadjuvant, adjuvant, and consolidation strategies, creating new decision points for thoracic surgeons, medical oncologists, radiation oncologists, pathologists, and payers. This shift is increasing the importance of coordinated diagnostic pathways that can deliver timely PD-L1 testing, next-generation sequencing, and pathology review before treatment initiation.

Combination approaches are also redefining standards of care. Chemo-immunotherapy has broadened eligibility for patients with varied PD-L1 expression, while dual-checkpoint strategies and immunotherapy combined with anti-angiogenic agents are being evaluated for selected patient profiles. Another major shift is the intensified focus on resistance biology, including primary resistance, acquired resistance, immune-excluded tumors, oncogene-driven lung cancers with lower immunotherapy responsiveness, and the tumor microenvironment. These dynamics are prompting clinical research into novel checkpoint targets, rational sequencing, treatment de-escalation in selected responders, and toxicity-reduction strategies.

Operationally, oncology systems are adapting to longer treatment journeys, survivorship needs, immune-related adverse event surveillance, and real-world evidence collection. Digital pathology, decentralized sample logistics, multidisciplinary tumor boards, and harmonized biomarker reporting are becoming critical enablers of high-quality immunotherapy delivery. The result is a more complex but more precise lung cancer care ecosystem in which clinical efficacy, diagnostic readiness, reimbursement governance, and safety monitoring must advance together.

Cumulative Impact of Artificial Intelligence on Checkpoint Inhibitor Care

Artificial intelligence is creating cumulative impact across the immune checkpoint inhibitor pathway for lung cancer, from early diagnosis and treatment selection to toxicity monitoring and real-world evidence generation. In imaging, AI-assisted radiomics is being investigated to extract quantitative features from CT, PET, and MRI scans that may correlate with tumor biology, response patterns, pseudoprogression, hyperprogression, and disease progression. In pathology, AI-enabled image analysis can support reproducible PD-L1 scoring workflows, tumor-infiltrating lymphocyte assessment, and tissue prioritization for molecular testing, while still requiring expert clinical validation and regulatory-grade quality controls.

AI is also improving the integration of complex multimodal data. Lung cancer treatment decisions increasingly depend on combining histology, smoking history, stage, PD-L1 status, genomic alterations, prior therapies, comorbidities, performance status, and laboratory parameters. Machine learning models can help identify patterns in electronic health records and clinical datasets that inform patient stratification, trial matching, and adverse event prediction. Natural language processing can further structure unstandardized oncology notes, radiology impressions, pathology reports, and immune-related toxicity documentation.

The most immediate value of AI lies in workflow acceleration and clinical decision support rather than autonomous treatment selection. Responsible deployment requires transparent algorithms, representative datasets, bias monitoring, interoperability with oncology information systems, cybersecurity safeguards, and evidence of clinical utility. As health systems adopt AI to support lung cancer immunotherapy, the strongest outcomes are expected where AI tools are embedded into biomarker-driven care pathways, multidisciplinary review, pharmacovigilance, and patient monitoring programs.

Key Regional Insights Across Global Lung Cancer Immunotherapy

Asia-Pacific is experiencing rapid evolution in immune checkpoint inhibitors for lung cancer due to a high lung cancer burden, expanding oncology infrastructure, and increased adoption of biomarker testing in major health systems. China, Japan, South Korea, India, and Australia are advancing clinical use through regulatory approvals, domestic clinical research, and broader hospital-based molecular diagnostics. Access remains heterogeneous, with urban cancer centers often offering more comprehensive immunotherapy services than rural or resource-constrained settings, making diagnostic scale-up and reimbursement clarity central to regional progress.

North America remains a highly developed region for lung cancer immunotherapy, supported by guideline-driven treatment pathways, extensive biomarker testing capacity, active clinical trial networks, and strong pharmacovigilance systems. The United States and Canada have integrated checkpoint inhibitors across multiple stages of non-small cell lung cancer, with growing emphasis on real-world outcomes, health equity, and toxicity management models. Reimbursement requirements, prior authorization processes, and variability in molecular testing coverage continue to shape treatment timeliness and patient access.

Latin America is advancing adoption of immune checkpoint inhibitors through improving cancer diagnostics, public-private oncology initiatives, and increasing specialist awareness. Brazil and Mexico are important regional centers for oncology care and clinical research; however, access to PD-L1 testing, next-generation sequencing, and immunotherapy reimbursement varies significantly by payer type, geography, and treatment setting. This creates a dual challenge of improving diagnostic equity and strengthening evidence-based access pathways.

Europe demonstrates broad clinical integration of checkpoint inhibitors, supported by centralized regulatory evaluation, national health technology assessments, and mature oncology guideline systems. Countries across Western Europe have incorporated immunotherapy into lung cancer standards, while Central and Eastern European access can be influenced by reimbursement timing, testing infrastructure, and national budget priorities. The region is also emphasizing real-world evidence, sustainable oncology spending, and harmonization of biomarker quality standards.

The Middle East is expanding advanced lung cancer treatment capabilities through investment in tertiary cancer centers, specialist training, and precision oncology programs, particularly in Gulf health systems. Access to checkpoint inhibitors is improving in major metropolitan centers, while regional disparities persist in diagnostic coverage and oncology workforce availability. Africa faces the greatest access constraints, with late-stage diagnosis, limited pathology capacity, uneven availability of PD-L1 testing, and affordability barriers affecting immunotherapy use. Across the continent, priorities include strengthening cancer registries, pathology networks, essential diagnostics, referral systems, and participation in context-appropriate clinical research.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are increasingly incorporating immune checkpoint inhibitors for lung cancer into tertiary oncology practice, although access differs widely between higher-resource urban centers and lower-resource provincial systems. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines show varying levels of diagnostic readiness, reimbursement maturity, and clinical trial participation. The region's core opportunity lies in improving standardized PD-L1 testing, expanding pathology capacity, and building referral pathways for advanced lung cancer management.

The GCC is progressing rapidly in precision oncology, supported by investment in specialist hospitals, national cancer strategies, and adoption of advanced therapeutics in countries with strong healthcare funding capacity. Lung cancer immunotherapy uptake is closely linked to centralized procurement, access to companion diagnostics, and the availability of multidisciplinary oncology teams. Regional priorities include improving screening awareness, capturing real-world outcomes, and developing immune-related adverse event protocols across institutions.

The European Union provides a structured environment for immune checkpoint inhibitor adoption through coordinated regulatory assessment, national reimbursement reviews, and guideline-based cancer care. While clinical standards are increasingly aligned, patient access timelines and biomarker testing reimbursement still vary among member states. EU-level emphasis on health data interoperability, cancer initiatives, and cross-border research collaboration supports continued improvement in lung cancer immunotherapy evidence generation.

BRICS countries represent a diverse group with large patient populations, expanding oncology capabilities, and significant variability in access. China has become a major contributor to lung cancer immunotherapy research and approvals, India is expanding access through oncology networks and molecular diagnostics growth, Brazil and Russia continue to balance reimbursement and infrastructure challenges, and South Africa faces access constraints linked to diagnostic and funding limitations. Across BRICS, scalable biomarker testing, local clinical evidence, and affordable care delivery are central to broader adoption.

G7 countries generally demonstrate advanced clinical integration of checkpoint inhibitors, supported by mature regulatory systems, sophisticated diagnostics, and active cancer research ecosystems. The group is increasingly focused on optimizing treatment duration, managing financial toxicity, improving inclusion of older adults and comorbid patients, and using real-world evidence to refine clinical practice. NATO countries overlap substantially with high-income oncology systems in North America and Europe, but also include members with varied reimbursement capacity and infrastructure maturity. Within this group, the emphasis is on healthcare resilience, secure medical supply chains, interoperable health data, and maintaining access to advanced cancer care during system disruptions.

Key Country Insights for Lung Cancer Checkpoint Inhibitors

The United States has deeply integrated immune checkpoint inhibitors into lung cancer care through guideline-based use, comprehensive biomarker testing, broad clinical trial activity, and established immune-related toxicity management. Canada follows a publicly funded oncology model where provincial reimbursement decisions, centralized cancer agencies, and biomarker access influence treatment consistency. Mexico is expanding immunotherapy availability in private and selected public settings, though diagnostic access and affordability remain important barriers.

Brazil is the leading Latin American country for advanced oncology adoption, with growing use of checkpoint inhibitors in major cancer centers and ongoing challenges related to public system reimbursement and molecular testing access. The United Kingdom has incorporated lung cancer immunotherapy through national evaluation frameworks, rapid cancer diagnostic pathways, and real-world evidence programs. Germany benefits from strong specialist care, pathology infrastructure, and biomarker testing capacity, while France emphasizes national oncology planning, structured reimbursement evaluation, and multidisciplinary cancer care.

Russia has clinical expertise in oncology and access to immunotherapy in selected settings, but regional variation in diagnostics and reimbursement can affect patient pathways. Italy and Spain have integrated checkpoint inhibitors across lung cancer indications through national and regional health systems, with ongoing attention to treatment appropriateness, budget governance, and equitable biomarker testing. China has rapidly advanced lung cancer immunotherapy through domestic clinical research, expanding approvals, and growth in hospital-based precision medicine, while managing large-scale access and reimbursement complexity.

India is seeing increased adoption in major metropolitan oncology centers, supported by growing molecular diagnostics and specialist expertise, but out-of-pocket costs and uneven diagnostic infrastructure limit broad access. Japan has extensive clinical experience with checkpoint inhibitors, mature pharmacovigilance, and strong guideline adherence, with careful attention to immune-related adverse events in an aging population. Australia combines strong oncology networks, public reimbursement mechanisms, and clinical trial participation to support evidence-based immunotherapy access. South Korea has advanced cancer centers, high diagnostic sophistication, and active research in lung cancer immunotherapy, with payer policies and biomarker criteria shaping real-world utilization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation by aligning clinical development, diagnostic partnerships, and patient access strategies around biomarker-defined lung cancer populations. Investment in high-quality PD-L1 testing, next-generation sequencing workflows, liquid biopsy validation, and standardized pathology reporting can reduce treatment delays and improve therapeutic precision. Clinical programs should continue to address unmet needs in early-stage lung cancer, resistance after checkpoint inhibitor exposure, oncogene-driven tumors, elderly patients, patients with autoimmune comorbidities, and populations underrepresented in trials.

Commercial and medical affairs teams should strengthen education around immune-related adverse event recognition, multidisciplinary management, and treatment sequencing. Collaboration with health systems can support infusion capacity planning, toxicity triage pathways, survivorship monitoring, and real-world data capture. Access strategies should be tailored to local reimbursement environments and should include diagnostic funding solutions, outcomes evidence, and support for equitable patient identification.

Technology leaders should focus on clinically validated AI and digital tools that improve workflow efficiency, trial matching, imaging assessment, pathology consistency, and remote symptom monitoring. Regulatory, medical, and market access teams must ensure that claims are supported by robust clinical evidence, real-world validation, and transparent safety reporting. The organizations best positioned in lung cancer immunotherapy will be those that integrate therapeutic innovation with diagnostic readiness, patient-centered care delivery, and measurable real-world value.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified, data-backed sources relevant to immune checkpoint inhibitors for lung cancer. The research approach includes review of peer-reviewed oncology literature, regulatory documents, clinical practice guidelines, health technology assessments, public health publications, clinical trial registries, cancer agency resources, and pharmacovigilance references. Evidence is prioritized from authoritative sources such as national and international oncology guidelines, regulatory labels, major medical journals, cancer registries, and public health institutions.

The methodology emphasizes qualitative synthesis rather than market sizing or forecasting. Key themes are assessed across clinical utility, treatment pathways, biomarker requirements, safety considerations, regional access dynamics, healthcare infrastructure, and emerging technology integration. Regional, group, and country insights are interpreted through available evidence on lung cancer burden, diagnostic capacity, reimbursement structures, clinical adoption patterns, health system maturity, and oncology workforce availability.

To maintain reliability, findings are cross-checked across multiple credible sources where possible, and claims are framed conservatively when evidence varies by jurisdiction or patient subgroup. The analysis excludes speculative estimates and avoids unsupported commercial assumptions. The resulting summary is designed to support strategic understanding of the immune checkpoint inhibitor landscape while remaining grounded in validated clinical and healthcare-system evidence.

Conclusion

Immune checkpoint inhibitors have fundamentally changed lung cancer treatment by enabling durable responses for selected patients and expanding therapeutic options across disease stages. Their continued impact depends on precise patient selection, timely biomarker testing, effective management of immune-related adverse events, and equitable access to advanced diagnostics and oncology expertise. The field is moving toward earlier intervention, rational combinations, improved resistance management, and broader use of real-world evidence to refine clinical practice.

Regional and country-level adoption patterns show that scientific progress alone is not sufficient; outcomes also depend on reimbursement structures, pathology capacity, oncology workforce availability, and care coordination. Artificial intelligence and digital health tools offer meaningful support for imaging, pathology, patient monitoring, and evidence generation, but their value will depend on validation, transparency, and integration into clinical workflows.

For stakeholders across the lung cancer immunotherapy ecosystem, the strategic imperative is clear: align innovation with diagnostics, safety, access, and real-world performance. Organizations that build scalable, evidence-driven, and patient-centered models will be better positioned to support the next phase of immune checkpoint inhibitor use in lung cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type

  • 7.1. Introduction
  • 7.2. PD-1 Inhibitors
  • 7.3. PD-L1 Inhibitors
  • 7.4. CTLA-4 Inhibitors

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen

  • 8.1. Introduction
  • 8.2. Combination Therapy
    • 8.2.1. With Chemotherapy
    • 8.2.2. With Targeted Therapy
  • 8.3. Monotherapy

9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line Of Therapy

  • 9.1. Introduction
  • 9.2. First Line
  • 9.3. Second Line
  • 9.4. Third Or Later

10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy
  • 10.5. Specialty Pharmacy

11. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Home Care Settings
  • 11.4. Hospitals
  • 11.5. Oncology Clinics

12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Immune Checkpoint Inhibitors for Lung Cancer Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Immune Checkpoint Inhibitors for Lung Cancer Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AstraZeneca plc
  • 16.2. Bristol-Myers Squibb Company
  • 16.3. Celgene Corporation
  • 16.4. F. Hoffmann-La Roche AG
  • 16.5. Genentech, Inc.
  • 16.6. Innovent Biologics, Inc.
  • 16.7. Lepu Biopharma Co., Ltd.
  • 16.8. Merck & Co.
  • 16.9. Ono Pharmaceutical Co. Ltd
  • 16.10. Regeneron Pharmaceuticals
  • 16.11. Shanghai Junshi Biosciences Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL WITH CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WITH CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WITH CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WITH TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WITH TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WITH TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THIRD OR LATER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THIRD OR LATER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THIRD OR LATER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SPECIALTY PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 116. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 137. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 144. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 255. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025